JERUSALEM--(BUSINESS WIRE)--Jan. 25, 2006--Teva Pharmaceutical Industries Limited (Nasdaq: TEVA) announced today that, subject to market and other conditions, it intends, through several special purpose finance subsidiaries, to offer $2.75 billion of debt securities comprised of: approximately $1.5 billion of senior notes in two series maturing in 2016 and 2036; approximately $750 million of convertible senior debentures maturing in 2026, which may be redeemed by Teva’s finance subsidiary in five years and repurchased by Teva’s finance subsidiary at investors’ option in five, ten or fifteen years; and approximately $500 million of convertible senior debentures maturing in 2026, which may be redeemed by Teva’s finance subsidiary in two years and repurchased by Teva’s finance subsidiary at investors’ option in two, five, ten or fifteen years.
